MX2012003230A - Composiciones farmaceuticas de rapamicina. - Google Patents

Composiciones farmaceuticas de rapamicina.

Info

Publication number
MX2012003230A
MX2012003230A MX2012003230A MX2012003230A MX2012003230A MX 2012003230 A MX2012003230 A MX 2012003230A MX 2012003230 A MX2012003230 A MX 2012003230A MX 2012003230 A MX2012003230 A MX 2012003230A MX 2012003230 A MX2012003230 A MX 2012003230A
Authority
MX
Mexico
Prior art keywords
rapamycin
pharmaceutical compositions
compositions
relates
solubility
Prior art date
Application number
MX2012003230A
Other languages
English (en)
Inventor
Brian Charles Keller
Nian Wu
Original Assignee
Brian Charles Keller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brian Charles Keller filed Critical Brian Charles Keller
Publication of MX2012003230A publication Critical patent/MX2012003230A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta invención se refiere a métodos y composiciones para mejorar la solubilidad y el perfil farmacocinético de la rapamicina. Más particularmente, la presente invención se refiere a emplear conjugados mono o diacil lipídicos-poliméricos para la formulación de composiciones de rapamicina que tienen mayor solubilidad y una mejor liberación.
MX2012003230A 2009-09-19 2010-09-18 Composiciones farmaceuticas de rapamicina. MX2012003230A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27695309P 2009-09-19 2009-09-19
PCT/US2010/002547 WO2011034606A1 (en) 2009-09-19 2010-09-18 Pharmaceutical compositions of rapamycin

Publications (1)

Publication Number Publication Date
MX2012003230A true MX2012003230A (es) 2012-04-10

Family

ID=43758948

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003230A MX2012003230A (es) 2009-09-19 2010-09-18 Composiciones farmaceuticas de rapamicina.

Country Status (3)

Country Link
US (1) US20110105387A1 (es)
MX (1) MX2012003230A (es)
WO (1) WO2011034606A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102292078A (zh) 2008-11-11 2011-12-21 得克萨斯大学体系董事会 哺乳动物雷帕霉素靶蛋白的抑制
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
CA3206208A1 (en) 2013-12-31 2015-07-09 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7868162B2 (en) * 1998-12-30 2011-01-11 Lakewood-Amedex, Inc. Antimicrobial and antiviral compounds and methods for their use
GB0008785D0 (en) * 2000-04-10 2000-05-31 Novartis Ag Organic compounds
US6610322B1 (en) * 2000-12-20 2003-08-26 Brian Charles Keller Self forming, thermodynamically stable liposomes and their applications
US6641611B2 (en) * 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant

Also Published As

Publication number Publication date
US20110105387A1 (en) 2011-05-05
WO2011034606A1 (en) 2011-03-24

Similar Documents

Publication Publication Date Title
JOP20180102B1 (ar) مركب صيدلاني
MX341825B (es) Compuestos de heteroarilo y usos de los mismos.
EP4253395A3 (en) Processes for the preparation of carbohydrate conjugated rna agents
MY181898A (en) Heterocyclic compounds and uses thereof
MX342709B (es) Tratamiento contra el cancer.
UA106507C2 (uk) Кон'югати димерів піроло[1,4]бензодіазепіну як протираковий засіб
MX2012006549A (es) Composiciones y metodos que comprenden variantes de proteasa.
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
MX348823B (es) Formulaciones estables de linaclotida.
WO2011057262A3 (en) Treatment of infections with tp receptor antagonists
MX2009004862A (es) Estabilizacion de vacunas por liofilizacion.
MX2012004780A (es) Inhibidores de akt.
WO2009115084A3 (de) Pyrrolopyrimidin-derivate und deren verwendungen
MX2012001691A (es) Composiciones de linaclotida que se desintegran oralmente.
MX2012003230A (es) Composiciones farmaceuticas de rapamicina.
TN2012000105A1 (en) Spirolactam derivatives and uses of same
UA103996C2 (en) Ivabradine hydrobromide
TR200900882A2 (tr) Tadı ve kokusu maskelenmiş, bıyoyararlanımı yüksek farmasotık bileşimler.
MY165088A (en) Pharmaceutical compositions comprising alisporivir
EP2611799A4 (en) PHARMACEUTICAL COMPOSITIONS OF LINEZOLID
MX2012004282A (es) Composiciones farmaceuticas.
WO2011021230A3 (en) Complexes for treatment and/or prophylaxis of parasitic infections
GB2509470A (en) Pharmaceutical compositions of antihypertensives
UA42812U (ru) Использование мази тиотриазолина в качестве агента, обладающего фотопротекторными свойствами